Acquisition of Oncological Pharmaceutical Product - Alectinib 150 mg Tablet

This tender, Process DIRECTA-PROC-50-2023-CENARES/MINSA-1, is for the direct acquisition of a specific oncological pharmaceutical product. The item required is Alectinib, presented in 150 mg tablet form. The procuring entity is the National Center for the Supply of Strategic Health Resources (CENARES), operating under the Ministry of Health (MINSA) in Peru. This procurement is critical for ensuring the availability of essential cancer treatment medication for patients. The method of contracting is Direct Contracting, which is typically used in specific circumstances where competitive bidding may not be feasible or appropriate, such as for specialized medical supplies or when there is a sole supplier. The acquisition aims to meet the healthcare needs of patients requiring Alectinib for their oncological treatment, underscoring CENARES' role in managing and supplying vital medicines within the national health system. The focus is on securing a consistent and timely supply of this high-value pharmaceutical to support patient care.

This is a supplies contract in the health and medical services sector, with a focus on Pharmaceuticals. Located in Peru, Latin America, this opportunity is open to firms and consortiums, with an estimated budget of PEN 4.1 million.

Published through Peru SEACE, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.